John Edward Robinson net worth and biography

John Robinson Biography and Net Worth

Insider of Cogent Biosciences

John Robinson is Cogent’s Chief Scientific Officer with over 20 years of small molecule drug discovery experience. He previously served as Vice President of Medicinal Chemistry at Pfizer Boulder Research and Development. John joined Pfizer from Array BioPharma, where he was Executive Director/Head of Chemistry. He started with Array in 2002 and served in a series of scientific and people leadership positions. He received his undergraduate degree in BioChemistry from Indiana University of Pennsylvania and his PhD in Synthetic Organic Chemistry from the University of Delaware. John spends a lot of time coaching high school baseball and youth football in Brighton, CO.

What is John Edward Robinson's net worth?: The estimated net worth of John Edward Robinson is at least $5.30 million as of December 26th, 2025. Robinson owns 140,002 shares of Cogent Biosciences stock worth more than $5,302,016 as of January 14th. This net worth evaluation does not reflect any other assets that Robinson may own. Additionally, Robinson receives an annual salary of $749,890.00 as Insider at Cogent Biosciences. Learn More about John Edward Robinson's net worth.
How old is John Edward Robinson?: Robinson is currently 49 years old. There are 3 older executives and no younger executives at Cogent Biosciences. Learn More on John Edward Robinson's age.
What is John Edward Robinson's salary?: As the Insider of Cogent Biosciences, Inc., Robinson earns $749,890.00 per year. There are 3 executives that earn more than Robinson. The highest earning executive at Cogent Biosciences is Mr. Andrew R. Robbins M.B.A., President, CEO & Director, who commands a salary of $1,060,000.00 per year. Learn More on John Edward Robinson's salary.
How do I contact John Edward Robinson?: The corporate mailing address for Robinson and other Cogent Biosciences executives is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. Cogent Biosciences can also be reached via phone at (617) 945-5576 and via email at [email protected]. Learn More on John Edward Robinson's contact information.
Has John Edward Robinson been buying or selling shares of Cogent Biosciences?: John Edward Robinson has not been actively trading shares of Cogent Biosciences during the last ninety days. Most recently, John Edward Robinson sold 90,000 shares of the business's stock in a transaction on Friday, December 26th. The shares were sold at an average price of $38.74, for a transaction totalling $3,486,600.00. Following the completion of the sale, the insider now directly owns 140,002 shares of the company's stock, valued at $5,423,677.48. Learn More on John Edward Robinson's trading history.
Who are Cogent Biosciences' active insiders?: Cogent Biosciences' insider roster includes John Green (CFO), Evan Kearns (Insider), John Robinson (Insider), and Jessica Sachs (Insider). Learn More on Cogent Biosciences' active insiders.
Are insiders buying or selling shares of Cogent Biosciences?: In the last twelve months, Cogent Biosciences insiders bought shares 1 times. They purchased a total of 2,777,777 shares worth more than $24,999,993.00. In the last twelve months, insiders at the technology company sold shares 3 times. They sold a total of 237,642 shares worth more than $9,200,345.40. The most recent insider tranaction occured on December, 26th when insider Evan Kearns sold 65,000 shares worth more than $2,515,500.00. Insiders at Cogent Biosciences own 7.3% of the company. Learn More about insider trades at Cogent Biosciences.
Information on this page was last updated on 12/26/2025.

John Edward Robinson Insider Trading History at Cogent Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/26/2025	Sell	90,000	$38.74	$3,486,600.00	140,002

John Edward Robinson Buying and Selling Activity at Cogent Biosciences

Cogent Biosciences Company Overview

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $37.79

$35.09

$38.36

50 Day Range

MA: $36.55

$14.72

$42.11

2 Week Range

Now: $37.79

$3.72

$43.73

Volume

1,932,867 shs

Average Volume

2,143,219 shs

Market Capitalization

$5.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

John Robinson Biography and Net Worth

What is John Edward Robinson's net worth?

How old is John Edward Robinson?

What is John Edward Robinson's salary?

How do I contact John Edward Robinson?

Has John Edward Robinson been buying or selling shares of Cogent Biosciences?

Who are Cogent Biosciences' active insiders?

Are insiders buying or selling shares of Cogent Biosciences?